Stocks are hitting the ceiling! Since October, 10 A-share listed companies have announced being targeted, with china national medicines corporation and sh pharma being targeted on the same day by new china life insurance.
① According to incomplete statistics, since October, 10 A-share listed companies including zhejiang east crystal electronic, semiconductor manufacturing international corporation, quanjinhao, lifecome biochemistry, zhejiang jingu, primeton information technologies, inc., guangzhou goaland energy conservation tech, xuzhou handler special vehicle, china national medicines corporation, and sh pharma have announced that they have received major stock purchases from relevant parties (see attached table). ② In the secondary market, this week, xuzhou handler special vehicle and guangzhou goaland energy conservation tech have both seen their stock prices increase by more than 100% since September.
Zhangzhou pientzehuang pharmaceutical "curved" acquisition of Fujian cosunter pharmaceutical? The innovative drugs sector sees the reappearance of traditional chinese medicine industry players | Read the announcement quickly.
Fujian Cosunter Pharmaceutical announced that the Yuanshan Fund intends to become a shareholder with more than 5% stake in the company through a transfer payment of nearly 0.2 billion yuan. The partners of the Yuanshan Fund consist of a wholly state-owned company and a wholly-owned subsidiary of zhangzhou pientzehuang pharmaceutical, among which the investment from zhangzhou pientzehuang pharmaceutical is the largest limited partner in the fund.
"Going global" and "innovation" are the key words that cannot be bypassed. Sun Piaoyang from Jiangsu Hengrui Pharmaceuticals, Zhu Yi from Baheal Pharm and other top pharmaceutical industry leaders jointly discuss the next decade | Industry Observation
On November 14, 2024, the opening ceremony of the Insight Conference was held in Chengdu, where experts in the pharmaceutical industry, investors, and chairmen of top listed companies exchanged views on the challenges and opportunities facing the China meheco group. The two key themes of "going global" and "innovation" ran through the entire conference. Faced with the question of the future direction of innovative drugs in China, various enterprises also provided different answers.
Innovative phar (00399.HK) will hold a board of directors meeting on November 29 to approve the interim performance.
According to a statement on November 14 by the innovative phar (00399.HK), the board of directors will hold a meeting on Friday, November 29, 2024, to consider and approve the consolidated interim results for the six months ended September 30, 2024, for the company and its subsidiaries.
Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.
①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.
Innovative Phar intends to acquire a majority stake in Niraxx. Inc.
Innovative Phar (00399) announced that on November 12, 2024, the company, as an investor, has entered into a memorandum of understanding with the target (Niraxx. Inc.), indicating its intention to invest in the majority equity of the target. It is reported that the target is a limited company registered in Delaware, usa, mainly engaged in (a) developing the ai-driven virtual health platform SyncWell; (b) developing the brain neural technology service platform DeepSynaps; (c) integrating optical biological regulation technology into sportswear; and (d) developing